Pharmaceutical

Abcuro secures $200m as it eyes approval for rare muscle disease drug

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Feb 13, 2025 - 06:00
Abcuro secures $200m as it eyes approval for rare muscle disease drug
The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.
Read the original article

Tags:

Previous Article

AbbVie and Xilio to collaborate on antibody-based immunotherapies

Next Article

OCT West Coast 2025: China surpasses US for annual number of clinical trials

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Labeling Excellence: The Art and Science Behind Capmatic's Advanced Labeling Solutions

Labeling Excellence: The Art and Science Behind Capmati...

Aug 28, 2023

Biotech survey highlights where industry can focus for a thriving future  

Biotech survey highlights where industry can focus for ...

Jul 12, 2024

Merck buys Mirus Bio to boost viral vector bioprocessing capacity

Merck buys Mirus Bio to boost viral vector bioprocessin...

Aug 3, 2024